Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY

Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis

“…TSEBT can be used for all disease stages in MF, but response rates are inversely related to the extent of skin disease (3,9). A patient with T1/T2 disease who receives a standard treatment dose of 30 to 36 Gy will have a CR rate of at least 80%, and with T3 disease, 40% (3,9,17). Response rate also depends on treatment dose (10,17).…”

“…A patient with T1/T2 disease who receives a standard treatment dose of 30 to 36 Gy will have a CR rate of at least 80%, and with T3 disease, 40% (3,9,17). Response rate also depends on treatment dose (10,17). A recent review of Stanford data addressing dose-response relationship for TSEBT in a population of 102 MF patients with T2 to T4 disease showed CR rates of 16% for patients receiving 5 to <10 Gy, 35% for 10 to <20 Gy, 34% for 20 to <30 Gy, and 62% for doses >30 Gy (10).…”

Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)

“…Many authors published encouraging results concerning its feasibility and efficacy, providing remission, stabilization, or palliation of symptoms (2,(5)(6)(7)16). Such a technique is able to deliver a skin surface dose above 30 Gy (usually 35-36 Gy) delivered with electrons of at least 4-MeV (usually 6-MeV) energy (2)(3)(4). The question of whether TSEBT is superior to topical mechlorethamine and ultraviolet light (psoralen -ultraviolet-light [PUVA]) therapy is still in debate (7,8,10).…”

Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the S�zary syndrome)

“…The intention was to deliver lymphoma-appropriate doses of radiation to the entire skin surface. Techniques were similar at Hamilton 2,17,24,25 and Yale. 20,21,22 Patients were treated with TSEB in the standing position and using a standard six-field arrangement.…”

“…Both the median age and the male-to-female ratio for patients with a new diagnosis of erythrodermic mycosis fungoides (Stages III-IV) are greater than those for patients with Stages IA-IIB. 2,17 Fifteen of the 45 patients received a consultation for a new diagnosis of mycosis fungoides, and 30 received a consultation after having failed at least one other therapy for the disease prior to referral to either Hamilton or Yale. Forty-three patients had erythroderma at the time of initial diagnosis.…”